Grünenthal Acquires Valinor Pharma for Approximately $250M

Novartis AG Acquires Chinook Therapeutics

June 12, 2023

Biotechnology

Novartis AG agreed to acquire Chinook Therapeutics for $40 per share in cash, with contingent value rights of up to $4 per share tied to regulatory milestones —bringing total consideration to as much as approximately $3.5 billion. The acquisition, approved by both companies' boards, brings Chinook's kidney-disease pipeline into Novartis' renal portfolio and was expected to close in the second half of 2023 subject to customary conditions.

Graybar Acquires Valin Corporation

May 1, 2023

Industrial Services

Graybar has entered into an agreement to acquire Valin Corporation, a San Jose–based distributor of automation, filtration, fluid handling, heating and process control products and systems that operates 12 locations across the western and southwestern United States. Valin will continue to operate under its existing name and leadership team as a Graybar subsidiary; the transaction was expected to close May 1, 2023.

Partners Group Acquires Pharmathen from BC Partners

July 19, 2021

Pharmaceuticals

Partners Group has agreed to acquire Pharmathen, the leading European drug delivery technology and pharmaceutical manufacturing company, from BC Partners in a transaction valued at approximately EUR 1.6 billion. The deal transfers control of Pharmathen to Partners Group (acting on behalf of its clients) and is aimed at supporting the company’s continued growth — including an intensified push into the US market — building on strong R&D and manufacturing capabilities.

Novolex Acquires Pactiv Evergreen Inc.

April 1, 2025

Packaging

Novolex has completed its combination with Pactiv Evergreen Inc. in a transaction valued at approximately $6.7 billion (including net debt), with Pactiv Evergreen shareholders receiving $18.00 per share and Pactiv Evergreen delisted from Nasdaq. The combined company will operate under the Novolex name, expanding manufacturing footprint, product breadth and R&D capabilities across food, beverage and specialty packaging markets.

Pfizer Acquires Biohaven Pharmaceutical Holding Company Ltd.

October 3, 2022

Pharmaceuticals

Pfizer Inc. completed the acquisition of Biohaven Pharmaceutical Holding Company Ltd. for approximately $11.6 billion (at $148.50 per share), bringing the migraine therapy NURTEC ODT (rimegepant), the zavegepant NDA program, and a CGRP-focused pipeline into Pfizer's Internal Medicine portfolio. Prior to closing, Biohaven spun off its non-CGRP assets into a separate publicly traded company, Biohaven Ltd., which Pfizer received a small pro rata stake in.

Indivior Acquires Opiant Pharmaceuticals

November 14, 2022

Pharmaceuticals

Indivior PLC will acquire Opiant Pharmaceuticals, Inc. for $20.00 per share in cash (approximately $145 million aggregate) plus up to $8.00 per share in contingent value rights tied to OPNT003 revenue milestones. The acquisition strengthens Indivior's addiction-treatment portfolio by adding Opiant's OPNT003 intranasal opioid overdose candidate and earlier-stage pipeline assets, and is expected to be accretive after the second full year of OPNT003 launch.